Santhera Pharmaceuticals Holding AG
SANN
Rank in Stocks
#16483
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company,... Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Share Price
$17.43
Market Cap
$266.65M
Change (1 day)
-3.10%
Change (1 year)
40.10%
Country
CH
Trade Santhera Pharmaceuticals Holding AG (SANN)
Category
Healthcare
Stock price history for Santhera Pharmaceuticals Holding AG (SANN)
Highest end of day price: $18.92 on 2026-10-01
Lowest end of day price: $44.13 on 2014-03-01
Lowest end of day price: $44.13 on 2014-03-01
Stock price history of Santhera Pharmaceuticals Holding AG from 2014 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 22.24% |
| 2025 | 42.98% |
| 2024 | -6.16% |
| 2023 | 41.12% |
| 2022 | -43.82% |
| 2021 | -53.14% |
| 2020 | -74.39% |
| 2019 | -17.31% |
| 2018 | -49.89% |
| 2017 | -38.99% |
| 2016 | -48.52% |
| 2015 | -16.32% |
| 2014 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $532.09 | 24.77% |
US
|
|
| $236.63 | 781.30% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $889.94 | 9.31% |
NL
|
|
| $291.42 | 2.39% |
BE
|
